<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775840</url>
  </required_header>
  <id_info>
    <org_study_id>BLO K026</org_study_id>
    <secondary_id>2007-003070-26</secondary_id>
    <secondary_id>D-CAN-546</secondary_id>
    <secondary_id>U1111-1113-9515</secondary_id>
    <nct_id>NCT00775840</nct_id>
  </id_info>
  <brief_title>Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.</brief_title>
  <official_title>Candesartan &quot;Added&quot; Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of candesartan, once daily (QD), on the&#xD;
      N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic&#xD;
      heart failure with diastolic dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart diseases are the number one cause of death in developed countries and in particular&#xD;
      chronic or congestive heart failure is the leading cause of hospitalization in patients older&#xD;
      than 65 years. It is still increasing in prevalence and, in spite of significant advances in&#xD;
      therapy, mortality rates remain high: 30% to 40% of patients with advanced disease, and 5% to&#xD;
      10% of patients with mild symptoms will die within 5 to 10 years.&#xD;
&#xD;
      A relevant proportion of the heart failure patients (30 - 50%) suffering from edema and&#xD;
      dyspnea have normal or minimally impaired left ventricular ejection fraction (preserved left&#xD;
      ventricular ejection fraction) with diastolic abnormalities in echocardiography. Features of&#xD;
      diastolic dysfunction are the stiffness, the decreased compliance and the impaired relaxation&#xD;
      of the left ventricle. As a result, the left ventricle has a limited filling capacity during&#xD;
      a normal left atrial pressure.&#xD;
&#xD;
      Hypertension and/or diabetes are the most predisposing conditions whereas left ventricular&#xD;
      hypertrophy is regarded as the linking intermediate pathological condition. Moreover, recent&#xD;
      studies showed that patients with symptomatic heart failure and an ejection fraction greater&#xD;
      than 40% have a poor prognosis with relatively high mortality and hospitalization rates.&#xD;
      Thus, in hypertensive patients, diastolic dysfunction has shown to be a predictor of&#xD;
      morbidity.&#xD;
&#xD;
      Diastolic dysfunction is also a frequent finding in type 2 diabetes without symptoms and&#xD;
      signs of heart disease. As long as it is independent of ischemic heart disease, it is&#xD;
      presumably due to diabetic cardiomyopathy. Once aggravated to heart failure, diastolic&#xD;
      dysfunction often coexists with systolic dysfunction as a consequence of coronary artery&#xD;
      disease with a limited coronary reserve.&#xD;
&#xD;
      This study will determine whether pharmacological intervention into the Renin Angiotensin&#xD;
      Aldosterone System exerted by the Angiotensin-Receptor Blocker Candesartan on top of an&#xD;
      Angiotensin-Converting Enzyme Inhibitor-based therapy may lead to a significant drop of&#xD;
      N-terminal pro-B-type Natriuretic Peptide. This neurohormonal laboratory marker is sufficient&#xD;
      enough to simultaneously indicate the improvement of the causing diastolic dysfunction and&#xD;
      associated heart failure symptoms as assessed by objective echocardiographic and clinical&#xD;
      parameters.&#xD;
&#xD;
      Total time for participants in this study is approximately 26 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from Baseline in N-terminal pro-B-type Natriuretic Peptide biomarker.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in N-terminal pro-B-type Natriuretic Peptide (log-transformed).</measure>
    <time_frame>Weeks 6 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Short Form-36 Health Survey score.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cystatin C.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Adiponectin.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glycosylated Hemoglobin.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Urinary Albumin Excretion.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in estimated Glomerular Filtration Rate and Cystatin C.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in New York Heart Association classification results.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiograms.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations of N-terminal pro-B-type Natriuretic Peptide with New York Heart Association Classification Results.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations of N-terminal pro-B-type Natriuretic Peptide with short Form-36 Health Survey Score.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations of N-terminal pro-B-type Natriuretic Peptide with Blood Pressure Results.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup evaluations regarding beta-blocker therapy and New York Heart Association class (II/III).</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup evaluations in terms of the different possible dosages of study medication.</measure>
    <time_frame>Weeks 6 to 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup evaluations based on different baseline levels of estimated Glomerular Filtration Rate.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup evaluations based on different baseline levels of Cystatin C.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup evaluations based on different baseline levels of N-terminal pro-B-type Natriuretic Peptide.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison from Baseline on the concomitant use of Loop Diuretics.</measure>
    <time_frame>Weeks 6 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition from sinus rhythm to permanent atrial fibrillation based on electrocardiogram recordings.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of preserved (Left Ventricular Ejection Fraction greater than or equal to 45%) to impaired systolic dysfunction (Left Ventricular Ejection Fraction less than 45%), based on echocardiographic results.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Candesartan QD + Heart Failure Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with angiotensin-converting enzyme-inhibitors/beta-blockers)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD + Heart Failure Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(with angiotensin-converting enzyme-inhibitors/beta-blockers)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.</description>
    <arm_group_label>Candesartan QD + Heart Failure Therapy</arm_group_label>
    <other_name>BLOPRESS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.</description>
    <arm_group_label>Placebo QD + Heart Failure Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus type 2 - insulin dependent or orally treated or managed by diet for&#xD;
             at least 3 Months.&#xD;
&#xD;
          -  Normotension or controlled hypertension with sitting Systolic Blood Pressure less than&#xD;
             140 mmHg and/or sitting Diastolic Blood Pressure less than 90 mmHg.&#xD;
&#xD;
          -  Regular sinus rhythm or atrial fibrillation with a medicamental-achieved rate control&#xD;
             of less than 100 bpm as confirmed by electrocardiogram recordings.&#xD;
&#xD;
          -  Echocardiographic evidence of a preserved Left Ventricular Ejection Fraction greater&#xD;
             than or equal to 45% (assessed by the modified Simpson method), with further&#xD;
             doppler-echocardiographic criteria for diastolic dysfunction grade I-IV.&#xD;
&#xD;
          -  New York Heart Association classification of II or III in a stable condition since at&#xD;
             least 3 months.&#xD;
&#xD;
          -  Existing background heart failure therapy with an Angiotensin-Converting Enzyme&#xD;
             Inhibitor alone or together with further preparations in a constant regimen since at&#xD;
             least 1 month, in case of beta-blockers since at least 3 months.&#xD;
&#xD;
          -  N-terminal pro-B-type Natriuretic Peptide greater than or equal to 250 pg/ml measured&#xD;
             at screening visit or collected from a dated previous laboratory document not older&#xD;
             than 3 months.&#xD;
&#xD;
          -  No previous therapy with Angiotensin-Receptor Blockers during the last 4 weeks prior&#xD;
             to the study.&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active must agree to use adequate&#xD;
             contraception, and can neither be pregnant nor lactating from Screening throughout the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired renal function (serum creatinine greater than 2.2 mg/dl or greater than 194&#xD;
             μmol/l).&#xD;
&#xD;
          -  Known bilateral renal artery stenosis or interventional treatment for renal artery&#xD;
             stenosis in the last year.&#xD;
&#xD;
          -  State after kidney transplantation.&#xD;
&#xD;
          -  Serum potassium greater than 5.5 mmol/l or glycosylated hemoglobin greater than 9.5 %.&#xD;
&#xD;
          -  Cor pulmonale or primary pulmonary disease with dyspnea at rest.&#xD;
&#xD;
          -  Known disposition to episodes of symptomatic hypotension or sitting Systolic Blood&#xD;
             Pressure less than 95 mmHg at baseline.&#xD;
&#xD;
          -  Acute coronary syndrome or any form of unstable chronic Coronary Artery Disease where&#xD;
             the indication of a coronary intervention is either planned in short or medium term or&#xD;
             can not be clearly excluded for the period of the study.&#xD;
&#xD;
          -  Any history of: myocardial infarction, previous Percutaneous Transluminal Coronary&#xD;
             Angioplasty with revascularization, stent implantation, Coronary Artery Bypass Graft&#xD;
             or open heart surgery.&#xD;
&#xD;
          -  Tachycardia at rest greater than 100 bpm as confirmed by electrocardiogram recordings.&#xD;
&#xD;
          -  Known clinically relevant rhythm disorders (e.g., tachyarrhythmias, salves of&#xD;
             supraventricular or ventricular extrasystoles or atrial fibrillation without&#xD;
             ventricular rate control) or symptoms suggesting a significant rhythm disorder (e.g.,&#xD;
             recurrent syncopes).&#xD;
&#xD;
          -  Primary valvular diseases and/or restrictive or obstructive cardiomyopathy.&#xD;
&#xD;
          -  Existing ventricular assist devices.&#xD;
&#xD;
          -  Relevant liver diseases (cholestasis or alanine aminotransferase/aspartate&#xD;
             aminotransferase greater than 2 times the upper limit of normal or gamma-&#xD;
             glutamyltransferase greater than 3 times the upper limit of normal).&#xD;
&#xD;
          -  History of primary hyperaldosteronism, of cancer in the last 5 years or of another&#xD;
             wasting disease with life expectancy of less than 2 years.&#xD;
&#xD;
          -  Known hypersensitivity to Candesartan Cilexetil.&#xD;
&#xD;
          -  Is required to take or intends to continue taking any disallowed medication, any&#xD;
             prescription medication, herbal treatment or over-the counter medication that may&#xD;
             interfere with evaluation of the study medication, including:&#xD;
&#xD;
               -  Need for maintenance therapy with Non-steroidal anti-inflammatory drugs or&#xD;
                  Cox-2-inhibitors.&#xD;
&#xD;
               -  Use of other Angiotensin-Receptor Blockers.&#xD;
&#xD;
          -  Any history of life-threatening diseases.&#xD;
&#xD;
          -  History of drug addiction and/or an extensive use of alcohol.&#xD;
&#xD;
          -  Acute coronary syndrome or unstable angina pectoris and any coronary artery disease&#xD;
             that was not stable during the last 3 months prior to inclusion.&#xD;
&#xD;
          -  Patients who are dependent on a permanently paced pacemaker (i.e. a patient with a&#xD;
             device that is not pacing during the echocardiographic examination can enter the&#xD;
             study).&#xD;
&#xD;
          -  Open heart surgery for other reasons than coronary revascularization&#xD;
&#xD;
          -  Participation in another clinical investigation within 30 days prior to enrolment or&#xD;
             for the course of the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Pharma Gmbh, Aachen (Germany)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bad Friedrichshall</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludwigsburg</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Homburg</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limburg</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melsungen</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mühlheim</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nienburg</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northeim</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weyhe</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gelsenkirchen</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gladbeck</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Langenfeld</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paderborn</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siegen</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Kreuznach</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neukirchen</city>
        <state>Saarland</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coswig</city>
        <state>Sachsen-Anhalt</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartmannsdorf</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leisnig</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Machem</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Markkleeberg</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riesa</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wermsdorf</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nordhausen</city>
        <state>Thüringen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>June 17, 2010</last_update_submitted>
  <last_update_submitted_qc>June 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Takeda Pharma Gmbh, Aachen (Germany)</organization>
  </responsible_party>
  <keyword>Cardiac Failure</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

